The GLP-1 ad wars “Healthy Skepticism” comes weeks after Eli Lilly competitor and Ozempic-maker Novo Nordisk launched a print campaign urging people to “Check Before You Inj

Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, launched a new advertising campaign on Friday warning patients about off-brand versions of its treatments, saying “they put people at risk.

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, the growing measles outbreak in Texas,

Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma. | Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma.

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn’t stopped the

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ farnesoid X receptor (FXR) agonist programme, aimed at treating inflammatory bowel disease (IBD).

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. | Eli Lilly has acquired Organovo’s lead asset,